AFTER Pfizer, a member of the Vaccine Experts Panel (VEP) is expecting Moderna to be the next manufacturer to be granted by the Food and Drug Administration (FDA) a Certificate of Product Registration (CPR) for its coronavirus disease (COVID-19) vaccine.
In an interview, VEP member Dr. Rontgene Solante said he expects Moderna to be the second brand of bivalent COVID-19 vaccines that will be commercially available in the Philippines.
“Moderna applied in the first quarter of this year. The approval timeline (for a CPR) is three to six months,” Solante said.
On Monday, the FDA announced the granting of a CPR for the bivalent dose of Pfizer Inc., which applied last February 2023. The CPR that was granted is for the booster injection for 12 years of age and older.
The approval of the Pfizer CPR, according to the FDA, comes after the extensive evaluation of the Task Force Edward, scientific community, and researchers.
With a CPR on hand, Pfizer is can now engage in the marketing, importation, exportation, sale, offer for sale, distribution, transfer, promotion, and advertisement of its COVID-19 vaccine.
